Trials / Completed
CompletedNCT04132570
A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide | Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days. |
| OTHER | Placebo | Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days. |
Timeline
- Start date
- 2019-10-22
- Primary completion
- 2020-01-22
- Completion
- 2020-01-22
- First posted
- 2019-10-21
- Last updated
- 2021-01-22
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04132570. Inclusion in this directory is not an endorsement.